Evidence map›Paper›PMID 31915934›Full record

ArticlePharmaceutical research2020

Assessment of Antibody Self-Interaction by Bio-Layer-Interferometry as a Tool for Early Stage Formulation Development.

Martin Domnowski, Jan Jaehrling, Wolfgang Frieß

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Martin DomnowskiDepartment of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Butenandtstrasse 5, 81377, Munich, Germany.
Jan JaehrlingDepartment of Protein Sciences and CMC, MorphoSys AG, Semmelweisstrasse 7, 82152, Planegg, Germany.
Wolfgang FrießDepartment of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Butenandtstrasse 5, 81377, Munich, Germany. Wolfgang.friess@lrz.uni-muenchen.de.ORCID http://orcid.org/0000-0002-8807-309X
MorphoSys (Germany) · DELudwig-Maximilians-Universität München · DE

Funding

Bayerische Forschungsstiftung 1251-16
6 · The paper itself

Abstract

purposeTo speed up the drug development process in the biopharmaceutical industry, high throughput methods are indispensable for assessing drug candidates and potential lead formulations, in particular during late stages of discovery and early phases of development. This study aimed to establish a bio-layer-interferometry based high throughput assay for assessing formulation dependent mAb self-interaction (SI-BLI) and to compare the results with k

methodsSelf-interaction of proprietary and commercially available mAbs was analyzed by SI-BLI and dynamic light scattering (DLS).

resultsWe found significant correlations of the SI-BLI results and k

conclusionsThe SI-BLI results correlate with k

Indexed as

AdalimumabDrug CompoundingHigh-Throughput Screening AssaysHumansInterferometryKineticsOmalizumabProtein BindingProtein ConformationProtein MultimerizationAdalimumabOmalizumabantibodybio-layer-interferometrydiffusion interaction parameterhigh concentration formulationSelf-interaction

Identifiers

PMID31915934
OpenAlexW3000229829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.